Moleculin Biotech Reports Financial Highlights and Future Plans [Yahoo! Finance]
Moleculin Biotech, Inc. (MBRX)
Last moleculin biotech, inc. earnings: 8/16 05:35 pm
Check Earnings Report
US:NASDAQ Investor Relations:
moleculin.com/investors
Company Research
Source: Yahoo! Finance
Moleculin Biotech, Inc. is a clinical-stage pharmaceutical company focused on developing treatments for hard-to-treat cancers and viruses, leveraging discoveries licensed from MD Anderson Cancer Center. The recent earnings report highlights significant financial and operational developments for the company. Moleculin reported no revenues for the period, with a net loss of $10.6 million for the three months ended September 30, 2024, compared to a $5.6 million loss in the same period in 2023. The company has been actively managing its financial liabilities, including significant warrant activities contributing to its financial results. Looking forward, Moleculin Biotech is preparing for a Phase 3 trial for its lead program, Annamycin, while seeking additional funding to support ongoing operations and clinical trials. Management remains focused on strategic partnerships for future commercialization opportunities. Pfizer Considers Selling Hospital Unit to Free Up Cash and Reduce Debt
Show less
Read more
Impact Snapshot
Event Time:
MBRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MBRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MBRX alerts
High impacting Moleculin Biotech, Inc. news events
Weekly update
A roundup of the hottest topics
MBRX
News
- Moleculin Biotech, Inc. (NASDAQ: MBRX) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- New Findings Show Moleculin's Annamycin Overcomes Resistance to Venetoclax in AMLPR Newswire
- Moleculin Accelerates Planned Unblinded Data Readout for MIRACLE Phase 3 R/R Acute Myeloid Leukemia (AML) Pivotal Trial to H2 2025 [Yahoo! Finance]Yahoo! Finance
- Moleculin Accelerates Planned Unblinded Data Readout for MIRACLE Phase 3 R/R Acute Myeloid Leukemia (AML) Pivotal Trial to H2 2025PR Newswire
- Moleculin Biotech, Inc. (NASDAQ: MBRX) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
MBRX
Analyst Actions
- 11/12/24 - Maxim Group
MBRX
Sec Filings
- 11/18/24 - Form 8-K
- 11/18/24 - Form 8-K
- 11/14/24 - Form SC
- MBRX's page on the SEC website